Repeated treatment courses of rituximab produce sustained efficacy in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs

被引：0
|
作者：
Emery, Paul [1 ]
Furst, Daniel E. [2 ]
Ferraccioli, Gianfranco [3 ]
Udell, James [4 ]
van Vollenhoven, Ronald F. [5 ]
Rowe, Karen [6 ]
Shaw, Tim [6 ]
机构：
[1] Leeds Gen Infirmary, Dept Rheumatol, Leeds, W Yorkshire, England
[2] Univ Calif Los Angeles, Rheumatol Clin Res Ctr, Los Angeles, CA USA
[3] Univ Cattolica Sacro Cuore, Dept Rheumatol, Rome, Italy
[4] Arthritis Grp, Philadelphia, PA USA
[5] Karolinska Univ Hosp, Stockholm, Sweden
[6] Roche Prod Ltd, Med Sci, London, England
来源：
RHEUMATOLOGY | 2008年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：II46 / II46
页数：1
相关论文
共 50 条
  • [1] Repeated treatment courses of rituximab produce sustained efficacy in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs
    Emery, Paul
    Khraishi, Majed
    Furst, Daniel
    Ferracioli, Gianfranco
    Udell, James
    van Vollenhoven, Ronald
    Rowe, Karen
    Agarwal, Sunil
    Shaw, Tim
    [J]. JOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1182 - 1182
  • [2] Sustained efficacy of repeat treatment courses of rituximab in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs
    Emery, P.
    Furst, D. E.
    Ferraccioli, G.
    Udell, J.
    van Vollenhoven, R. F.
    Rowe, K.
    Agarwal, S.
    Shaw, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 430 - 430
  • [3] Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs
    Emery, P.
    van Vollenhoven, R. F.
    Furst, D. E.
    Ferraccioli, G.
    Udell, J.
    Rowe, K.
    Agarwal, S.
    Shaw, T.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 : 40 - 41
  • [4] Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs
    Pavelka, Karel
    Kavanaugh, Arthur F.
    Rubbert-Roth, Andrea
    Ferraccioli, Gianfranco
    [J]. RHEUMATOLOGY, 2012, 51 : V12 - V21
  • [5] TREATMENT PATTERNS, PERSISTENCE, AND DURABILITY IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS)
    Dore, Robin K.
    Antonova, Jenya
    Burudpakdee, Chakkarin
    Wang, Xin
    Ozbay, Burak
    Genovese, Mark C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1135 - 1136
  • [6] EFFICACY AND SAFETY OF UPADACITINIB IN A CHINESE SUBGROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Zeng, X.
    Liu, Y.
    Hu, J.
    Li, J.
    Wang, Y.
    Zhao, D.
    Wu, L.
    Xiao, Z.
    Li, Z.
    Xu, J.
    Meerwein, S.
    Xie, Y.
    Liang, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1324 - 1324
  • [7] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    [J]. CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [8] Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Agarwal, S.
    Zaman, T.
    Handa, R.
    [J]. SINGAPORE MEDICAL JOURNAL, 2009, 50 (07) : 686 - 692
  • [9] Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor
    Albattal, Basel M.
    [J]. ANNALS OF SAUDI MEDICINE, 2016, 36 (03) : 190 - 196
  • [10] Treatment Patterns of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
    Jin, Yinzhu
    Liu, Jun
    Desai, Rishi
    Kim, Seoyoung
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3476 - 3479
12345